Compare AURA & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AURA | ZVRA |
|---|---|---|
| Founded | 2007 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 419.5M | 472.9M |
| IPO Year | 2021 | 2015 |
| Metric | AURA | ZVRA |
|---|---|---|
| Price | $6.97 | $9.79 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $19.00 | ★ $23.00 |
| AVG Volume (30 Days) | 309.2K | ★ 695.8K |
| Earning Date | 05-14-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 159.21 |
| EPS | N/A | ★ 1.35 |
| Revenue | N/A | ★ $106,470,000.00 |
| Revenue This Year | N/A | $37.27 |
| Revenue Next Year | N/A | $53.42 |
| P/E Ratio | ★ N/A | $7.43 |
| Revenue Growth | N/A | ★ 350.91 |
| 52 Week Low | $4.73 | $7.11 |
| 52 Week High | $7.68 | $13.16 |
| Indicator | AURA | ZVRA |
|---|---|---|
| Relative Strength Index (RSI) | 53.28 | 49.27 |
| Support Level | $5.94 | $8.20 |
| Resistance Level | $7.04 | $10.15 |
| Average True Range (ATR) | 0.33 | 0.38 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 35.78 | 29.69 |
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.